Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 13/20 | 0.62 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | CDK4 | P11802 | 2/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.52 |
| ▸ | CCND1 | P24385 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | CCND3 | P30281 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 6/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.47 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.45 |
| ▸ | STK25 | O00506 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5693205 | 1.00 | CHEK1 (0.62) | CHEK1CYP11B1CYP11B2LRRK2IDO1 | |
| SCHEMBL12764197 | 0.85 | CHEK1 (0.62) | CHEK1CYP11B1CYP11B2CDK4CDK1 | |
| SCHEMBL2458765 | 0.84 | CHEK1 (0.67) | CHEK1LRRK2CDK4CDK1CCNA2 | |
| SCHEMBL2458766 | 0.84 | CHEK1 (0.67) | CHEK1LRRK2CDK4CDK1CCNA2 | |
| SCHEMBL30633894 | 0.83 | CHEK1 (0.63) | CHEK1LRRK2CDK4CDK1CCNA2 | |
| SCHEMBL7502145 | 0.82 | CYP11B1 (0.51) | CHEK1CYP11B1CYP11B2CDK4CDK1 | |
| SCHEMBL7502157 | 0.82 | CYP11B1 (0.51) | CHEK1CYP11B1CYP11B2CDK4CDK1 | |
| SCHEMBL5922396 | 0.82 | CHEK1 (0.53) | CHEK1CYP11B1CYP11B2IDO1CDK4 | |
| SCHEMBL5922428 | 0.82 | CHEK1 (0.53) | CHEK1CYP11B1CYP11B2CDK4CDK1 | |
| SCHEMBL5922432 | 0.82 | CHEK1 (0.53) | CHEK1CYP11B1CYP11B2CDK4CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2015-11-05 | — | — | US | disclosed |
| US-8501812-B2 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-06 | — | — | US | disclosed |
| US-7897572-B1 | Theraputic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2011-03-01 | — | — | US | disclosed |
| US-20060281789-A1 | Protein kinase inhibitors | KYOWA HAKKO KOGYO CO., LTD (JP) | 2006-12-14 | — | — | US | disclosed |
| WO-2006104983-A1 | THERAPEUTIC METHODS FOR TYPE I DIABETES | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2006-10-05 | — | — | WO | disclosed |
| EP-1650194-A1 | PROTEIN KINASE INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-04-26 | — | — | EP | disclosed |
| US-20060058366-A1 | Jnk inhibitor | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-03-16 | — | — | US | disclosed |
| EP-1582211-A1 | JNK INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281789-A1 | Protein kinase inhibitors | MAP3K20, MAP3K1, MAP3K19 | CHEK1 247/4885CYP11B1 2579/4885CYP11B2 2948/4885 |
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | MAPK9, IAPP, RNASE1 | CHEK1 3913/4885CYP11B1 2550/4885CYP11B2 2627/4885 |
| US-20060058366-A1 | Jnk inhibitor | MAPK3, MAPK4, MAPKAPK3 | CHEK1 1169/4885CYP11B1 905/4885CYP11B2 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.